Literature DB >> 21284700

The effect of rectal ozone on the portal vein oxygenation and pharmacokinetics of propranolol in liver cirrhosis (a preliminary human study).

Saad Zaky1, Ehab Ahmad Fouad, Hassan Ibrahim Mohamad Kotb.   

Abstract

AIM: The aim of this study was to investigate the effect of rectal ozone on portal vein oxygenation and the pharmacokinetic changes of propranolol in patients with liver cirrhosis.
METHODS: Fifteen patients with liver cirrhosis were included They were given a fixed oral dose of propranolol 80mg on the morning of day 1 after overnight fasting. Blood samples were collected at fixed time intervals for 24h. Patients were given 12 sessions of rectal ozone of 300ml of 40% ozone/oxygen mixture. On day 14 another oral dose of 80mg propranolol was given and blood samples were collected as on day 1. Plasma concentrations of propranolol were measured by HPLC. Portal vein oxygen tension and saturation were measured before and after rectal ozone.
RESULTS: Plasma concentrations of propranolol were reduced after ozone therapy with pronounced decreases in the maximum plasma concentration and the area under the plasma concentration-time curve. The changes were consistent with a decrease in propranolol bioavailability. There was a decrease in the elimination half-life and mean residence time. Portal vein oxygenation significantly increased after rectal ozone.
CONCLUSIONS: The changes in the pharmacokinetics of propranolol probably reflect an increase in the rate and extent of its metabolism resulting from improved portal vein oxygenation attributable to the ozone therapy. The present work highlights that ozone can be an alternative medical measure to improve portal vein oxygenation in liver cirrhosis.
© 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21284700      PMCID: PMC3045550          DOI: 10.1111/j.1365-2125.2010.03851.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

2.  Bioavailability of propranolol after oral, sublingual, and intranasal administration.

Authors:  G S Duchateau; J Zuidema; F W Merkus
Journal:  Pharm Res       Date:  1986-04       Impact factor: 4.200

3.  Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease.

Authors:  D J Morgan; A J McLean
Journal:  Hepatology       Date:  1991-12       Impact factor: 17.425

4.  [Ozone-oxygen therapy in proctology].

Authors:  H G Knoch; W Klug
Journal:  Ter Arkh       Date:  1990       Impact factor: 0.467

5.  Protective effect of ozone treatment on the injury associated with hepatic ischemia-reperfusion: antioxidant-prooxidant balance.

Authors:  C Peralta; O S León; C Xaus; N Prats; E C Jalil; E S Planell; P Puig-Parellada; E Gelpí; J Roselló-Catafau
Journal:  Free Radic Res       Date:  1999-09

6.  Hepatic artery flow and propranolol metabolism in perfused cirrhotic rat liver.

Authors:  D G Le Couteur; H Hickey; P J Harvey; J Gready; A J McLean
Journal:  J Pharmacol Exp Ther       Date:  1999-06       Impact factor: 4.030

7.  Effects of ozone oxidative preconditioning on nitric oxide generation and cellular redox balance in a rat model of hepatic ischaemia-reperfusion.

Authors:  H H Ajamieh; S Menéndez; G Martínez-Sánchez; E Candelario-Jalil; L Re; A Giuliani; Olga Sonia León Fernández
Journal:  Liver Int       Date:  2004-02       Impact factor: 5.828

8.  Increased sensitivity of propranolol clearance to reduced oxygen delivery in the isolated perfused cirrhotic rat liver.

Authors:  P L Hickey; A J McLean; P W Angus; E F Choo; D J Morgan
Journal:  Gastroenterology       Date:  1996-10       Impact factor: 22.682

9.  Effect of ozone therapy on muscle oxygenation.

Authors:  Bernardino Clavo; Juan L Pérez; Laura López; Gerardo Suárez; Marta Lloret; Victor Rodríguez; David Macías; Maite Santana; Jesús Morera; Dolores Fiuza; Francisco Robaina; Martina Günderoth
Journal:  J Altern Complement Med       Date:  2003-04       Impact factor: 2.579

10.  Ozone Therapy for Tumor Oxygenation: a Pilot Study.

Authors:  Bernardino Clavo; Juan L. Pérez; Laura López; Gerardo Suárez; Marta Lloret; Victor Rodríguez; David Macías; Maite Santana; María A. Hernández; Roberto Martín-Oliva; Francisco Robaina
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

  10 in total
  5 in total

1.  Important details to be clarified about the effect of rectal ozone on the portal vein oxygenation.

Authors:  Velio Bocci; Iacopo Zanardi; Valter Travagli
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

2.  A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans.

Authors:  Michael E Saladin; Kevin M Gray; Aimee L McRae-Clark; Steven D Larowe; Sharon D Yeatts; Nathaniel L Baker; Karen J Hartwell; Kathleen T Brady
Journal:  Psychopharmacology (Berl)       Date:  2013-03-05       Impact factor: 4.530

Review 3.  Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19.

Authors:  Gregorio Martínez-Sánchez; Adriana Schwartz; Vincenzo Di Donna
Journal:  Antioxidants (Basel)       Date:  2020-05-06

4.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

Review 5.  Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility.

Authors:  Noel L Smith; Anthony L Wilson; Jason Gandhi; Sohrab Vatsia; Sardar Ali Khan
Journal:  Med Gas Res       Date:  2017-10-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.